AV000103A (ICVAX) vs BNT168

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV antigens · full HIV pipeline

AV000103A (ICVAX)

Developed by Immuno Cure BioTech

Phase 1 in HIVDNA vaccine
Weak signal

NCT06253533 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence of adverse events at week 36 [Safety and Tolerability]". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: March 2027 · NCT07530198 (registry estimate)

Reported efficacy

Incidence of adverse events at week 36 [Safety and Tolerability]: All 45 participants, randomised across 1 mg, 2 mg and 4 mg dosing groups at an ICVAX to placebo ratio of 12:3, completed the scheduled visits. All reported treatment-related adverse events were mild and no treatment-related severe adverse events occurred. Among those receiving the optimal dose, a large majority had a more than 2-fold increase in T cell responses.

Result source: NCT06253533

BNT168

Developed by BioNTech

Phase 1 in HIVmRNA vaccine
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2028 · NCT07698600 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAV000103A (ICVAX)BNT168
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

AV000103A (ICVAX)
—Not reported
BNT168
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

AV000103A (ICVAX)
—Not reported
BNT168
—Not reported

CD4 count, change (week 48)

AV000103A (ICVAX)
—Not reported
BNT168
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AV000103A (ICVAX): no structured comparison results are available for HIV.

BNT168: no structured comparison results are available for HIV.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AV000103A (ICVAX)'s landscape · BNT168's landscape